ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07618
-0,10%
Bitcoin
63.686,61
-0,32%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. Amneal Pharmaceuticals Holding Co (AMRX)

  7. Amneal Pharmaceuticals Holding Co (AMRX) News

AMRX

Amneal Pharmaceuticals (AMRX)

Amneal Pharmaceuticals Holding Co
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:AMRX
DatumZeitQuelleÜberschriftSymbolFirma
03/05/202412h14Edgar (US Regulatory)Form 8-K - Current reportNYSE:AMRXAmneal Pharmaceuticals Holding Co
03/05/202412h00Business WireAmneal Reports First Quarter 2024 Financial ResultsNYSE:AMRXAmneal Pharmaceuticals Holding Co
24/04/202414h00Business WireAmneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid OverdoseNYSE:AMRXAmneal Pharmaceuticals Holding Co
16/04/202414h00Business WireAmneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable MedicineNYSE:AMRXAmneal Pharmaceuticals Holding Co
10/04/202414h00Business WireAmneal to Report First Quarter 2024 Results on May 3, 2024NYSE:AMRXAmneal Pharmaceuticals Holding Co
28/03/202421h05Business WireAmneal to Ring the Nasdaq Closing Bell on April 2, 2024NYSE:AMRXAmneal Pharmaceuticals Holding Co
25/03/202421h05Business WireAmneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic SuspensionNYSE:AMRXAmneal Pharmaceuticals Holding Co
22/03/202413h01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNYSE:AMRXAmneal Pharmaceuticals Holding Co
22/03/202413h01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNYSE:AMRXAmneal Pharmaceuticals Holding Co
06/03/202423h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
06/03/202423h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
05/03/202422h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
05/03/202422h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
01/03/202412h13Edgar (US Regulatory)Form 8-K - Current reportNYSE:AMRXAmneal Pharmaceuticals Holding Co
01/03/202412h00Business WireAmneal Reports Fourth Quarter and Full Year 2023 Financial ResultsNYSE:AMRXAmneal Pharmaceuticals Holding Co
29/02/202422h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
27/02/202414h00Business WireAmneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203NYSE:AMRXAmneal Pharmaceuticals Holding Co
13/02/202414h00Business WireAmneal to Participate at Upcoming Investor ConferenceNYSE:AMRXAmneal Pharmaceuticals Holding Co
08/02/202422h05GlobeNewswire Inc.Amneal Announces Complete Response Resubmission for IPX203 New Drug ApplicationNYSE:AMRXAmneal Pharmaceuticals Holding Co
31/01/202422h05Business WireAmneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024NYSE:AMRXAmneal Pharmaceuticals Holding Co
10/01/202414h00Business WireAmneal Launches Complex Generic Fluorometholone Ophthalmic SuspensionNYSE:AMRXAmneal Pharmaceuticals Holding Co
04/01/202422h05Business WireAmneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023NYSE:AMRXAmneal Pharmaceuticals Holding Co
26/12/202322h10Edgar (US Regulatory)Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
26/12/202322h05Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NYSE:AMRXAmneal Pharmaceuticals Holding Co
21/12/202314h00Business WireAmneal to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:AMRXAmneal Pharmaceuticals Holding Co
15/12/202322h15Edgar (US Regulatory)Form 8-K - Current reportNYSE:AMRXAmneal Pharmaceuticals Holding Co
15/12/202322h06Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NYSE:AMRXAmneal Pharmaceuticals Holding Co
15/12/202322h05Business WireAmneal Announces Move to NasdaqNYSE:AMRXAmneal Pharmaceuticals Holding Co
07/12/202314h00Business WireAmneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)NYSE:AMRXAmneal Pharmaceuticals Holding Co
01/12/202322h15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NYSE:AMRXAmneal Pharmaceuticals Holding Co
 Showing the most relevant articles for your search:NYSE:AMRX

Kürzlich von Ihnen besucht

FX
EURUSD
Euro vs US Dollar
NYSE
KO
Coca Cola
USOTC
BASFY
BASF (QX)
NYSE
DIS
Walt Disney
NYSE
NKE
Nike
TG
RHM
Rheinmetall
AMEX
XLE
Energy Select Sector SPDR
NYSE
MRK
Merck
AMEX
XLV
Health Care Select Sector
TG
ALV
Allianz
NYSE
XOM
Exxon Mobil
COIN
ETHUSD
Ethereum
FX
EURJPY
Euro vs Yen
USOTC
ADDYY
Adidas (QX)
CCOM
US100
US Tech 100
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten